Get the Stockscreener App
2.57
0.00%
0.00
After Hours:
2.57
Esperion Therapeutics Inc stock is traded at $2.57, with a volume of 6.40M.
It is up +0.00% in the last 24 hours and up +22.38% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$2.57
Open:
$2.52
24h Volume:
6.40M
Relative Volume:
1.70
Market Cap:
$486.91M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.9113
EPS:
-2.82
Net Cash Flow:
$-135.49M
1W Performance:
+6.64%
1M Performance:
+22.38%
6M Performance:
+20.66%
1Y Performance:
+105.60%
1-Day Range:
$2.5106
$2.61
1-Week Range:
$2.305
$2.615
52-Week Range:
$1.1601
$3.40
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.57 | 486.91M | 116.33M | -209.25M | -135.49M | -2.82 |
|
ZTS
Zoetis Inc
|
175.70 | 79.27B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.59 | 43.23B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 42.56B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.79B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.08 | 15.61B | 15.05B | -883.30M | 1.89B | 1.53 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire
Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan
Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa
Esperion's chief commercial officer sells shares worth $426 - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times
Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat
ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com
Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com
Esperion Therapeutics: Growth Initiatives Are Paying OffBuy - Seeking Alpha
Esperion Therapeutics Q3 2024 Earnings Preview - MSN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Esperion Therapeutics: Q3 Earnings Snapshot - Darien Times
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y - Yahoo Finance
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times
Esperion Q3 Revenue Surges 52% to $51.6M as Prescription Growth Accelerates | ESPR Stock News - StockTitan
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to "Buy" - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Esperion Therapeutics Inc - GuruFocus.com
Esperion to Participate in Upcoming Jefferies London Healthcare Conference - GlobeNewswire
Esperion Announces a Featured Presentation in the Late - GlobeNewswire
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three - The Bakersfield Californian
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions - Yahoo Finance
Esperion Therapeutics (ESPR) Set to Announce Quarterly Earnings on Thursday - MarketBeat
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy - MarketBeat
Esperion to Report Third Quarter 2024 Financial Results on November 7 - GlobeNewswire
ESPREsperion Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexletol From Esperion - Pharmacy Times
Esperion Therapeutics' chief commercial officer sells shares worth $226 - Investing.com
Esperion Therapeutics' chief commercial officer sells shares worth $226 By Investing.com - Investing.com UK
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings - Yahoo Finance
INVA: 3 Small-Cap Biotech Stocks With Game-Changing Potential - StockNews.com
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Reduced by Zacks Research - MarketBeat
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):